GlassScriptPhysician profile
Purvi D Gada
NPI 1639209224
$75,754.17
in general payments reported to CMS, 2019-2025
14 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,278 · 2020: $3,478 · 2021: $7,269 · 2022: $11K · 2023: $11K · 2024: $16K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Consulting Fee: $21K · Honoraria: $2,275 · Food and Beverage: $1,323 · Travel and Lodging: $791 · Education: $16.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,520.00 |
| Consulting Fee | $21,390.00 |
| Honoraria | $2,275.00 |
| Food and Beverage | $1,322.70 |
| Travel and Lodging | $791.38 |
| Education | $16.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $49,045.89 | 2021-2025 | Imfinzi, Imjudo, Truqap |
| Gilead Sciences, INC. | $6,688.48 | 2021-2024 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $4,122.99 | 2019 | |
| Daiichi Sankyo INC. | $2,786.42 | 2020-2022 | |
| Glaxosmithkline, LLC. | $2,750.00 | 2021 | |
| Janssen Biotech, INC. | $2,250.00 | 2021-2023 | |
| Genzyme Corporation | $2,155.00 | 2019 | |
| Beigene USA, INC. | $1,925.00 | 2024 | Brukinsa |
| Deciphera Pharmaceuticals INC. | $1,448.98 | 2025 | Qinlock |
| Immunomedics, INC. | $1,225.00 | 2020 | |
| Aadi Bioscience, INC. | $1,000.00 | 2023 | Fyarro |
| Intera Oncology, INC | $186.96 | 2024 | Intera |
| Allergan, INC. | $120.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $49.45 | 2020-2024 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Purvi Gada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.